Member Info for Saxondale

Yep , a very similar proposition to Bex , ie offering multiple combination options to boost the efficacy of existing drugs .
Also AVCT got a very muted SP rise today ( albeit 60% up from a while ago )- a temporary situation I feel , as it dawns on the market what it actually means .
These are two pretty good shares to hold at the moment , as the impressive data from both companies will inevitably lead to licensing deals or takeovers down the road .

Hes delighted to say Dox is being released in the tumour , showing in ALL the tumour biopsies they have taken , in meaningful levels .

The study is as ' data rich as possible ' - essential for regulatory approvals , crucial to prove it is being released in the tumour.
'Extremely encouraging ' results on the safety profile regarding side effects and toxicity .

Major well done to all the team . And for investors this was one big milestone too . The relief is palpable !
Not easy waiting for these make or break news events , so to get this better than dreamed of update is a major moment .
Having been badly bruised by SNG last year , I was wary of going in too deep here , but sometimes you have to take educated gambles .
Wow what a great bit of news.

analysis of tumour biopsies obtained from six patients across several cohorts indicates that doxorubicin is being released within the tumour tissue confirming the tumour targeting potential of the pre|CISIONTM technology.

We are number 3 on the share risers leader board today on LSE .
Maybe we will start getting the attention we deserve .

All sites are in Finland, but the Company anticipates sites in the U.S. to be opened during Q1 2023 to speed up recruitment even further.

As well as two CR , the PR patient was one that previously hadn't responded to azacitidine previously - but with Bex - showed a response . Just the kind of proof they need to justify the efficacy .

Good call .

We now have 2 complete responders from first cohort !
Price tag just got increased.
· Objective response observed in 3 out of 5 patients in the first doublet cohort

· 2 of the 3 responders were refractory to prior azacitidine monotherapy

· No additional adverse events observed adding bexmarilimab to standard of care

· Rapid enrollment into both doublet and triplet combinations

LLS are very active in promoting and bring up new treatments .
Faron are in exactly the right company ( TAP partner) to get attention ( funding?) for Bex in the AML department .

Just put this out , a summary of ASH22 and what's coming in 2023 ( that's already been announced )

https://www.lls.org/blog/whats-next-blood-cancer-looking-ahead-2023?utm_source=Twitter&utm_medium=Social&utm_campaign=01-12-2023-LLS-Ash-Blog-Looking-Ahead-To-2023-ZGM

I think the rejig with IPF partners recently was perhaps to enable more flexible funding on the next tranches ( should they need it ) , just in case there were delays in FDA recommendations .
The whole process is a moving discussion , as the longer it goes on , the more Faron seem to unveil , and the price tag changes .
They've never been in a better position to actually do a deal than now .

Markku ( CEO) & Toni (CFO) are at JPM Conference , along with Alex Spicer ( Business Dev ) and Julia Balanova ( VP , Inv relations).
Not sure I've known this mix of the team to be at event like this before .

The JP Morgan lady in their promo video says that investors are looking for companies that have long patent dates , with novel treatments in areas with low competition , and with a clear pipeline to profit .
This event sometimes opens with a big blockbuster deal announcement ( lacking in last 2 years ) , but is the place where many licensing and partner deals are announced .
You are in the heart of the pharma investing world - where better place to showcase your new partner ?

Faron just announced they will be at the JP Morgan Healthcare Conference in San Fransisco next week .

This is a major event , lots of meetings , and quite often deals are done and signed .

https://www.jpmorgan.com/solutions/cib/insights/health-care-conference

https://twitter.com/FaronPharm/status/1610999243526782976?s=20&t=Dxmq8C3kuQ5cd-JgXmzxDQ

Markku was pressed on this issue at the last interview , and we had a long discussion regarding his confidence on the matter . Based on what he knew at the time - funding was not an 'issue' .
From which we could take it that he had options on the table .

In normal years , I may have taken that with the usual pinch of salt , as we have become used to the endless placing RNS's .
But with the BEXMAB results being so astoundingly good , and the Matins P2 dosing/biomarker package finally all done and presented to FDA , Faron are at last in a position to do a 'proper' deal .

Up until now , there were loose ends that needed to be finalised ( such as the dosing/soluble clever1 issue)
The picture just wasn't clear enough.
In my opinion they now have pretty much enough of the jigsaw put together that it meets the criteria of interested parties , who would not want to take on a 'half finished' study .

Firing up BEXMAB in such a short time was a gamble , especially while they were still working on MATINS , but boy has that paid off .

I'm excited to see what comes next.

I think the article relates to info already released , but with an 11% rise on naz , it shows how Faron are still are not even on the radar of many investors .

Lets hope the interest builds .
Nice start to the year .

The Finnish company's "miracle drug" produced revolutionary results - the patient's cancer was completely cured.

The new results are amazing

Newly released results show that the first patient to come to treatment, who had a previously reported partial response, has continued to gain strength.

After four cycles of treatment, the cancer cells in the bloodstream and bone marrow had disappeared and the blood count had returned to normal, meaning the patient had a complete response and the cancer was cured.

Well the Christie in Manchester is one of the trial sites for MATINS .
Not us specifically as we aren't approved , but shows that we are a. in the right place , b. being watched by the right people , and c. are front and centre part of the future of cancer treatment .

Aim , I'll buy some more if they push it down enough , otherwise I'll sit back .

The company only has an Mcap of £35m .
Hasn't even started getting going .
2023 will be transformational .
Investors don't give a hoot , they know whats coming .
Traders however will have a busy morning chasing this around .
I may buy some more - good luck

Must admit I didn't expect to be topping up again today , but 58p is frankly ridiculous .
That's about what I paid about a year ago - with about 8 months to wait for approval ( and not even certainty about that )
Oh well , shouldn't complain .
Got a nice pile now , so will sit back and see how they get on in 2023 .